NCT03072056View on ClinicalTrials.gov

A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 9, 2017

Primary Completion Date

July 7, 2017

Study Completion Date

July 7, 2017

Conditions
Healthy Subjects
Interventions
DRUG

MIN-101

Trial Locations (1)

BT2 7BA

Biokinetic Europe, Belfast

Sponsors
All Listed Sponsors
lead

Minerva Neurosciences

INDUSTRY